A dual pharmacological effect of escitalopram on alveolar bone loss in periodontitis

Key Points

• Escitalopram significantly decreases alveolar bone loss associated with periodontitis, enhancing dental health.
• A notable reduction of approximately 30% in bone loss was observed after 12 weeks of treatment with escitalopram.
• Assessment using pharmacological effects of escitalopram highlights its potential in treating periodontal disease.
• Further investigation is needed to confirm these findings in larger populations and diverse settings.